ABBV ▼ -1.2% - AbbVie Inc.
$ABBV - AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
30-SEP-2026 01:30 AM ET
Share this post
More filings for $ABBV
ABBV ▲ +1.3% - AbbVie Inc.Oct 19, 2026ABBV ▲ +1.3% - AbbVie Inc.Oct 17, 2026ABBV ▼ -2.4% - AbbVie Inc.Oct 13, 2026ABBV ▲ +1.5% - AbbVie Inc.Oct 11, 2026ABBV ▲ +0.6% - AbbVie Inc.Oct 7, 2026ABBV ▲ +0.6% - AbbVie Inc.Oct 5, 2026
View full $ABBV filing history →💬 Comments
Loading comments…
Leave a comment